BioSpace News Archive

CEL-SCI Corporation announced the closing of its previously announced public offering of 2,490,000 shares of its common stock to a single investor at a public offering price of $2.00 per share, for gross proceeds of approximately $5 million, before deducting underwriting discounts and offering expenses.

Edesa Biotech, Inc. (NASDAQ:EDSA) today announced favorable final results from a Phase 2b dose-ranging clinical study of the company’s drug candidate, EB01 (daniluromer), as a monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD).

Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 study evaluating AV-101, a novel dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), has completed enrollment at 202 adult patients.

MorphoSys AG announces strong topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.

SAB Biotherapeutics today announced that Katie Ellias has been appointed to the Company’s Board of Directors.

Zevra Therapeutics, Inc. today announced the completion of its acquisition of Acer Therapeutics Inc.

Cybin Inc. today announced that it will discuss its topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder, as part of an R&D investor briefing.

Imvax, Inc. today announced details of its two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting, which was held in Vancouver, British Columbia, Canada, from November 15-19, 2023.

QurAlis Corporation today announced that Kasper Roet , Ph.D., chief executive officer and founder, will present at the Piper Sandler 35th Annual Healthcare Conference being held November 28-30, 2023 in New York, NY.

Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.